Equities Research Analysts’ updated eps estimates for Tuesday, December 5th:

Embotelladora Andina (NYSE:AKO.B) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Embotelladora Andina S.A. produces and distributes Coca-Cola products in Chile, Brazil and Argentina. Through subsidiaries, they also produce PET packaging, produce and distribute juices and mineral water, and process and distribute agricultural products, including canned fruits and tomato products. “

AZZ (NYSE:AZZ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AZZ Inc. is a global provider of metal coating services, welding solutions, specialty electrical equipment and highly engineered services to the markets of power generation, transmission, distribution and industrial in protecting metal and electrical systems used to build and enhance the world’s infrastructure. AZZ Metal Coatings is a leading provider of metal finishing solutions for corrosion protection, including hot dip galvanizing to the North American steel fabrication industry. AZZ Energy is dedicated to delivering safe and reliable transmission of power from generation sources to end customers, and automated weld overlay solutions for corrosion and erosion mitigation to critical infrastructure in the energy markets worldwide. “

Byline Bancorp (NYSE:BY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Byline Bancorp, Inc. operates as a bank holding company serving small- and medium-sized businesses, financial sponsors and consumers. The Company offers saving accounts, credit cards, loans, mortgages, lending, equipment leasing, cash management and online banking services. Byline Bancorp, Inc. is headquartered in Chicago, Illinois. “

Clearwater Paper (NYSE:CLW) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Clearwater Paper,a standalone company,produces pulp and paperboard at six facilities across the country namely Lewiston, Idaho; Las Vegas, Nev.; Elwood, Ill.; and near McGehee, Ark. The company manufactures quality paperboard, consumer tissue, and wood products.It has direct access to the public capital markets .The company is a premier supplier of private label tissue to major retail grocery chains, and also produces bleached paperboard used by quality-conscious printers and packaging converters. “

Cognizant Technology Solutions (NASDAQ:CTSH) had its buy rating reiterated by analysts at BMO Capital Markets. BMO Capital Markets currently has a $78.00 price target on the stock.

CyberOptics (NASDAQ:CYBE) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “CyberOptics Corporation is a leading provider of sensors and inspection systems that provide process yield and through-put improvement solutions for the global electronic assembly and semiconductor capital equipment markets. The Company’s products are deployed on production lines that manufacture surface mount technology circuit boards and semiconductor process equipment. By increasing productivity and product quality, our sensors and inspection systems enable electronics manufacturers to strengthen their competitive positions in highly price-sensitive markets. Headquartered in Minneapolis, Minnesota, they conduct worldwide operations through facilities in North America, Asia and Europe. “

Daktronics (NASDAQ:DAKT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Daktronics Inc. has strong leadership positions in, and is one of the world’s largest suppliers of, electronic scoreboards, computer-programmable displays, and large screen video displays and control systems. The company excels in the control of large display systems, including those that require integration of multiple complex displays showing real-time information, graphics, animation and video. Daktronics designs, manufactures, markets and services display systems for customers around the world in sport, business and transportation applications. “

Easterly Government Properties (NYSE:DEA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Easterly Government Properties, Inc. is focused primarily on the acquisition, development and management of commercial properties leased to U.S. Government agencies through the U.S. General Services Administration. Easterly Government Properties, Inc. is based in Washington, District of Columbia. “

Diasorin (OTCMKTS:DSRLF) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “DiaSorin S.p.A. engages in the development, production and marketing of reagent kits for in vitro diagnostics. It specializes in the provision of immunodiagnostics and molecular diagnostics solutions which serves infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology clinical areas. DiaSorin S.p.A. is headquartered in Vercelli, Italy. “

Esperion Therapeutics (NASDAQ:ESPR) had its hold rating reissued by analysts at Chardan Capital. The analysts wrote, “We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors.””

LivaNova (NASDAQ:LIVN) had its hold rating reiterated by analysts at Canaccord Genuity. They currently have a $76.00 target price on the stock. The analysts wrote, “We remain HOLD-rated on shares of LIVN in the wake of their announcement that the company would purchase the remaining part of ImThera – an early-stage company focused on neuromodulation to treat obstructive sleep apnea – that it does not already own. While the technology fits synergistically within LIVN’s strong neuromodulation franchise to some degree, the call point will be different than its current offering (ENTs vs. neurosurgeons). The firm thinks it can leverage its growing OUS neuromodulation sales presence to drive some near-term ImThera revenue (expectations not disclosed) in Europe; however, we expect contributions will be minimal for the next few years at least, primarily on the basis of current reimbursement coverage, or lack thereof, and need for long-term data to catalyze ENT surgeons to adopt the therapy, according to our due diligence.””

Eli Lilly and (NYSE:LLY) was given a $73.00 price target by analysts at BMO Capital Markets. The firm currently has a sell rating on the stock.

lululemon athletica (NASDAQ:LULU) had its sell rating reiterated by analysts at Canaccord Genuity. They currently have a $43.00 price target on the stock. The analysts wrote, “LULU will report FQ3 results on Wednesday, December 6 AMC. We are modeling a 4% comp and 52c in EPS (vs. consensus comp of 5.3% and EPS of 52c); however, we believe there could be upside of ~200bps to our comp assumption and ~2c-3c to EPS largely driven by continued strength in men’s and improving outerwear sales. That said, we believe buyside expectations are high (and uniformly positive), with comp expectations in the 6-7% range, leaving little room for topping an already elevated bar. As for gross margin, now that much of the company’s supply chain recapture work has been completed, we are looking for only modest GM expansion (+16bps vs. flat guidance), and during the quarter, we noticed persistently elevated levels of inventory on the company’s We Made Too Much page (e.g. over 300 women’s styles on sale during much of October), even despite lululemon having had its third warehouse sale this year, a physical sale in Ontario at the end of September. Separately, a month ago, news of Creative Director Lee Holman’s resignation (for personal reasons”) after just two years in the role should have been cause for concern (his predecessor lasted only two years as well), however, that was overshadowed by the CEO’s commentary that referenced momentum in the business entering the holiday season. Since that announcement, the stock has been up 5% vs. the XRT +12% (700bps of weaker relative performance). Taking it together, while we see the likelihood of a Q3 EPS beat, we continue to see mounting evidence of our denim fashion shift thesis taking shape over the next 4-6 quarters and thus would use any strength as a selling opportunity.””

Pattern Energy Group (NASDAQ:PEGI) (TSE:PEG) was upgraded by analysts at Goldman Sachs Group Inc from a neutral rating to a buy rating.

Qudian (NYSE:QD) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $20.00 target price on the stock, down from their previous target price of $30.00.

Theravance Biopharma (NASDAQ:TBPH) had its buy rating reaffirmed by analysts at Needham & Company LLC. The analysts wrote, “We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline.””

Toll Brothers (NYSE:TOL) was downgraded by analysts at KeyCorp to an overweight rating.

Receive News & Ratings for Embotelladora Andina SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embotelladora Andina SA and related companies with MarketBeat.com's FREE daily email newsletter.